Max E. Link

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Part of Roche Holding AG, Corange Ltd. is a Bermudian company that manufactures orthopedic and diagnostics equipment. The private company is based in Hamilton, Bermuda. Corange was acquired by Roche Holding AG on May 01, 1997 for $10,930.22 million.

Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

Centerpulse AG was a medical technology group, which served the reconstructive joint, spinal and dental implant markets. Its subsidiaries developed, produced and distributed medical implants and biological materials for orthopedic, spinal and dental markets worldwide. The product array included artificial joints, dental implants, spinal implants and instrumentation. The company was headquartered in Zurich, Switzerland.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The private company is based in Basel, Switzerland.

Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria.

Part of Zimmer Biomet Holdings, Inc., ORTHOsoft ULC is a Canadian medical software development company. The private company is based in Montréal, Canada. Louis-Philippe Amiot has been the CEO of the company since 1995. ORTHOsoft ULC was acquired by Zimmer Biomet Holdings, Inc. on October 16, 2007 for $46.36 million.

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV.

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The private company is based in Camberley, UK and was founded in 1981.

Part of Roche Holding AG, Boehringer Mannheim Diagnostics Corp. develops and manufactures personal diagnostic devices. The private company is based in Houston, TX.

Mipharm SpA manufactures specialty pharmaceuticals and generic drugs. It operates as a third party manufacturing site for various pharmaceutical brands as well as offers integrated services such as packagaing, research, and development. The company was founded by Giuseppe G. Miglio in January 1998 and is headquartered in Milan, Italy.

Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.

Aeon Scientific AG engages in the development of medical devices for cardiac interventions. Its product supports electro physiologists during ablation procedures, such as for the treatment of Atrial Fibrillation. The technology is a platform with additional potential in other medical applications such as for gastroenterology, neurosurgery and targeted drug delivery in general. The company was founded by Dominik J. Bell in October 2010 and is headquartered in Zurich, Switzerland.